On multivariable analysis including NAFLD HCC, obesity, insulin-dependence, race/ethnicity, blood type, tumor burden, AFP and MELD-Na at listing, and number of LRT, there was still no difference between NAFLD-HCC and other-HCC patients (HR, 1.25; 95% CI, 0.89-1.76; P = 0.20). Here, AFP is linked to metabolic dysfunction-associated steatotic liver disease.